Galmed Pharma Secures New Patents for Aramchol Combination Therapy
Ticker: GLMD · Form: 6-K · Filed: Dec 4, 2025 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, MASH, licensing
Related Tickers: MDGL
TL;DR
Galmed just got new patents for combining Aramchol with Madrigal's Rezdiffra for MASH. Big IP win!
AI Summary
On December 4, 2025, Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining their drug Aramchol with Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) to treat MASH. This development is significant for Galmed's intellectual property portfolio and potential future therapeutic applications.
Why It Matters
These new patents strengthen Galmed's intellectual property position and could pave the way for new treatment options for MASH patients by combining their drug with an existing therapy.
Risk Assessment
Risk Level: medium — The company is announcing patent grants, which is positive, but the actual commercialization and success of the combined therapy are still uncertain.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- Aramchol (drug) — Galmed's drug
- Madrigal Pharmaceuticals (company) — Partnering company
- Rezdiffra (Resmetirom) (drug) — Madrigal's drug
- MASH (disease) — Condition being treated
- December 4, 2025 (date) — Date of announcement
FAQ
What is the specific nature of the new use patents granted to Galmed Pharmaceuticals?
The new use patents are for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for the treatment of MASH.
When was this announcement made by Galmed Pharmaceuticals?
The announcement was made on December 4, 2025.
What is the exact name of the company filing this report?
The exact name of the company is Galmed Pharmaceuticals Ltd.
What is the ticker symbol for Galmed Pharmaceuticals Ltd.?
The SEC file number is 001-36345, which often corresponds to a ticker symbol, but the ticker itself is not explicitly stated in this excerpt.
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report a press release issued by Galmed Pharmaceuticals Ltd. on December 4, 2025, regarding new use patents.
Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-12-04 08:42:40
Filing Documents
- form6-k.htm (6-K) — 18KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-25-026112.txt ( ) — 48KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: December 4, 2025 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer